L&C Bio Co. Ltd

290650 · KQ · Healthcare / Medical Devices

20,150.00KRW-1300.00 (-6.06%)

Price History

Full chart

Market Stats

Previous Close21,450.00

Open21,000.00

Day Range20,100.00 – 22,000.00

52-Week Range40,761.12 – 120,881.13

Volume484.35K

Market Cap1.41T

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.09%

Beta1.49

50-Day Avg52,003.07

200-Day Avg69,055.27

About

L&C BIO Co.,LTD operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C BIO Co.,LTD was founded in 2011 and is headquartered in Seongnam-si, South Korea.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Chul Lee Whan
Employees170
HeadquartersSuntechcity, Seongnam-si, South Korea, Korea
Websitehttps://www.lncbio.co.kr

Leadership

Mr. Chul Lee WhanChief Executive Officer

Financials

Income Statement

Currency: KRW	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	9.00B	11.82B	17.90B	21.24B	29.15B	32.97B	45.68B	52.57B	65.93B	72.09B	85.48B
Growth (%)	-	+31.37%	+51.42%	+18.66%	+37.24%	+13.11%	+38.53%	+15.10%	+25.40%	+9.35%	+18.56%
Cost of Revenue	4.69B	4.83B	6.76B	7.86B	10.49B	13.41B	17.23B	25.58B	32.07B	36.36B	40.09B
Gross Profit	4.31B	6.99B	11.14B	13.38B	18.66B	19.56B	28.45B	26.99B	33.86B	35.73B	45.39B
Gross Margin	47.87%	59.12%	62.21%	63.00%	64.02%	59.32%	62.29%	51.34%	51.35%	49.56%	53.10%
Operating Expense	3.19B	4.96B	6.26B	7.90B	9.63B	12.23B	15.28B	17.47B	28.10B	33.20B	40.97B
Operating Income	1.12B	2.03B	4.87B	5.48B	9.03B	7.32B	13.17B	9.52B	5.75B	2.52B	4.42B
Operating Margin	12.48%	17.16%	27.21%	25.79%	30.98%	22.21%	28.84%	18.12%	8.73%	3.50%	5.17%
EBITDA	-	-	-	-	-	-	-	12.15B	75.09B	149.80B	-145.93B
EBITDA Margin	-	-	-	-	-	-	-	23.11%	113.90%	207.78%	-170.73%
Net Income	1.20B	1.98B	3.75B	5.21B	7.25B	10.81B	13.81B	4.54B	48.36B	141.06B	-138.17B
Net Income Margin	13.36%	16.76%	20.97%	24.52%	24.87%	32.79%	30.24%	8.64%	73.36%	195.67%	-161.65%
R&D	-	-	-	-	1.49B	2.38B	2.29B	2.20B	3.15B	4.91B	4.10B
R&D as % of Total Revenue	-	-	-	-	5.12%	7.22%	5.02%	4.18%	4.78%	6.81%	4.80%
Interest Expense	0	0	0	0	0	743.24M	460.27M	3.08B	6.17B	3.22B	5.87B
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	2.25%	1.01%	5.85%	9.36%	4.47%	6.86%

Balance Sheet

Currency: KRW	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	9.11B	15.66B	20.49B	57.38B	66.23B	80.58B	107.40B	199.73B	262.23B	475.60B	456.64B
Total Liabilities	5.20B	5.64B	3.68B	4.92B	8.04B	22.77B	22.38B	101.77B	115.29B	191.25B	248.10B
Total Equity	3.91B	10.02B	16.81B	52.46B	58.18B	57.81B	85.02B	97.95B	146.94B	284.35B	198.22B
Cash	584.07M	382.66M	3.12B	12.31B	6.96B	4.64B	9.47B	6.59B	14.95B	18.29B	30.89B
Total Debt	2.68B	2.99B	-	1.00B	1.62B	14.66B	-	-	-	-	-
Net Debt	-	-	-	-	-	-	-	73.65B	64.91B	100.38B	55.55B

Cash Flow

Currency: KRW	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.33B	-185.35M	3.82B	3.85B	6.43B	7.42B	10.91B	-6.08B	-12.13B	-8.57B	12.56B
Investing Cash Flow	-452.87M	-4.21B	-625.30M	-16.76B	-15.81B	823.50M	-20.49B	-83.63B	24.63B	-21.95B	-
Financing Cash Flow	1.82B	4.20B	-451.33M	31.42B	526.87M	1.26B	4.70B	78.93B	-4.16B	33.83B	-
Capital Expenditure	276.10M	715.85M	285.34M	4.74B	1.96B	3.02B	10.25B	37.53B	24.98B	5.35B	17.04B
Free Cash Flow	-	-	-	-	-	4.36B	-521.15M	-43.78B	-37.12B	-13.92B	-4.47B
Dividends Paid	-	-	729.33M	729.33M	729.33M	729.33M	1.08B	1.11B	1.11B	2.27B	1.12B
FCF to OCF	-	-	-	-	-	58.82%	-4.78%	720.55%	305.92%	162.45%	-35.58%
Dividend Paid to FCF	-	-	-	-	-	16.71%	-206.79%	-2.55%	-3.00%	-16.30%	-25.11%

Earnings

Report Date	Mar 15, 2019	May 15, 2019	Aug 12, 2019	Nov 12, 2019	Feb 12, 2020	May 13, 2020	Aug 13, 2020	Nov 10, 2020	Mar 22, 2021	May 13, 2021	Aug 12, 2021	Nov 10, 2021	Feb 16, 2022	May 13, 2022	Aug 12, 2022	Nov 14, 2022	Feb 16, 2023	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Mar 24, 2026	May 11, 2026	Aug 14, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140.94
EPS Actual	59.67	71.00	93.67	74.81	89.77	72.67	79.00	85.58	255.04	87.00	81.00	77.00	375.00	56.00	50.00	14.00	80.47	25.57	58.42	2122.84	-145.21	66.15	45.40	-220.46	6191.80	-18.23	-561.36	-2213.27	-2877.18	101.31	-1059.00
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-851.38%
Timing	Pre-market	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	-	-	-	-	-	-	-	-	-	-	-	-	-	Pre-market

Key Statistics & Ratios

Market Cap1.41T

Enterprise Value1.22T

Trailing P/E0.00

Forward P/E0.00

Price / Sales12.19

Price / Book3.70

Revenue (TTM)116.30B

Gross Profit (TTM)68.23B

EBITDA27.42B

Profit Margin-128.47%

Operating Margin22.12%

Return on Equity-45.32%

Return on Assets2.38%

Shares Outstanding25.45M

Shares Float18.83M

Beta1.49

Dividend Yield0.09%

Dividend Rate48.35

Payout Ratio1.66%

Dividends

20251×

24.18Dec 29, 2025

20241×

24.18Dec 27, 2024

20231×

48.35Dec 27, 2023

20221×

24.18Dec 28, 2022

20211×

24.18Dec 29, 2021

20201×

24.18Dec 29, 2020

20191×

16.12Dec 27, 2019

Stock Splits

Oct 26, 20262:1
Sep 3, 2026698:675
Oct 12, 2020959692:319897